Vascular BioSciences is a biomedical company dedicated to developing innovative technologies to detect and treat vascular-based diseases such as cardiovascular disease, pulmonary vascular disease and cancer.

Many vascular-based diseases are poorly understood, difficult to diagnose, and frequently associated with significant morbidity and mortality because of the inaccessibility of vascular tissue. To extend the length and quality of patient life, Vascular BioSciences has created the world’s first endoarterial biopsy catheter, a device designed to obtain biopsy specimens from the inner layers of an artery via a minimally invasive technique.

Vascular BioSciences is committed to improving current patient therapy and disease management by providing a more comprehensive picture of a patient's vascular pathological, cellular, molecular, and genetic profile through the use of our first product, the endoarterial biopsy catheter.

The endoarterial biopsy catheter will provide a means for monitoring therapeutic interventions, optimizing medical management, customizing diagnosis and therapy, and anticipating future adverse events through the early identification of disease markers in vascular biopsies from patients. Biopsy samples will undergo histopathological and molecular analysis to identify each patient’s disease expression. Pharmaceutical therapeutics can then be administered to precisely target disease pathways.

Vascular BioSciences focuses on focuses on improving the diagnosis and medical management of primary and secondary pulmonary hypertension, acute and chronic lung transplant rejection, vasculitis, pulmonary manifestations of collagen vascular diseases such as lupus and scleroderma, and primary and secondary lung cancer, coronary artery disease, peripheral vascular disease, and pharmaceutical drug discovery and development.

Vascular BioSciences develops interventional devices, molecular diagnostics and pharmaceuticals in order to enhance and prolong human life.